NASDAQ:INSMInsmed Stock Price, Forecast & News

Insmed's stock was trading at $21.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, INSM stock has increased by 20.1% and is now trading at $25.53. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Insmed.

Insmed is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Insmed.

Insmed Incorporated (NASDAQ:INSM) released its quarterly earnings results on Thursday, April, 30th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the Zacks' consensus estimate of ($0.72) by $0.02. The biopharmaceutical company earned $36.90 million during the quarter, compared to analyst estimates of $34.81 million. Insmed had a negative net margin of 162.82% and a negative return on equity of 87.35%. The business's quarterly revenue was up 68.5% on a year-over-year basis. During the same period in the previous year, the company earned ($0.96) EPS. View Insmed's earnings history.

8 brokers have issued 12-month price objectives for Insmed's shares. Their forecasts range from $20.00 to $56.00. On average, they anticipate Insmed's stock price to reach $42.00 in the next twelve months. This suggests a possible upside of 64.5% from the stock's current price. View analysts' price targets for Insmed.

News coverage about INSM stock has trended somewhat positive recently, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Insmed earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an effect on the stock's share price in the near term. View the latest news aboutInsmed.

Insmed saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 13,480,000 shares, an increase of 12.2% from the April 15th total of 12,010,000 shares. Based on an average daily volume of 1,440,000 shares, the days-to-cover ratio is presently 9.4 days. Approximately 15.8% of the company's shares are sold short. View Insmed's Current Options Chain.

Some companies that are related to Insmed include Ono Pharmaceutical (OPHLF), Horizon Therapeutics (HZNP), Mylan (MYL), Elanco Animal Health (ELAN), Dr.Reddy's Laboratories (RDY), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), ACADIA Pharmaceuticals (ACAD), Bausch Health Companies (BHC), Ascendis Pharma A/S (ASND), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Myokardia (MYOK), Forty Seven (FTSV) and Emergent Biosolutions (EBS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include AbbVie (ABBV), Geron (GERN), Johnson & Johnson (JNJ), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Intercept Pharmaceuticals (ICPT), Micron Technology (MU), Opko Health (OPK) and Amarin (AMRN).

Insmed trades on the NASDAQ under the ticker symbol "INSM."

Insmed's stock is owned by a number of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (9.83%), Franklin Resources Inc. (2.21%), Eagle Asset Management Inc. (1.67%), Geode Capital Management LLC (1.48%), Carillon Tower Advisers Inc. (1.25%) and Fairmount Funds Management LLC (1.14%). Company insiders that own Insmed stock include Alfred Altomari, Donald J Hayden Jr, John Goll, Melvin Md Sharoky, Orlov S Nicole Schaeffer, Roger Adsett, Steinar J Engelsen and William Lewis. View institutional ownership trends for Insmed.

INSM stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Russell Investments Group Ltd., Foresite Capital Management IV LLC, Foresite Capital Management II LLC, JPMorgan Chase & Co., Granahan Investment Management Inc. MA, Raymond James & Associates, and Rafferty Asset Management LLC. Company insiders that have sold Insmed company stock in the last year include John Goll, Orlov S Nicole Schaeffer, and William Lewis. View insider buying and selling activity for Insmed.

INSM stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., William Blair Investment Management LLC, AXA, Cormorant Asset Management LP, Lord Abbett & CO. LLC, Scout Investments Inc., Geode Capital Management LLC, and WCM Investment Management LLC. Company insiders that have bought Insmed stock in the last two years include Melvin Md Sharoky, Roger Adsett, Steinar J Engelsen, and William Lewis. View insider buying and selling activity for Insmed.

Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INSM stock can currently be purchased for approximately $25.53.

Insmed has a market capitalization of $2.58 billion and generates $136.47 million in revenue each year. The biopharmaceutical company earns $-254,340,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. Insmed employs 373 workers across the globe.

The official website for Insmed is www.insmed.com.

Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]